Barclays’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q1
Sell
-63,100
Closed -$1.01M 7311
2014
Q4
$1.01M Sell
63,100
-884,800
-93% -$12.9M ﹤0.01% 3207
2014
Q3
$12.3M Buy
+947,900
New +$11.3M 0.01% 1028
2013
Q4
Sell
-191,400
Closed -$3.25M 7731
2013
Q3
$3.25M Buy
+191,400
New +$3.67M ﹤0.01% 2086

Other funds holding INFI

Barclays's INFI Position: Q1 2023 in Review

Barclays sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2023, closing a stake of 359 shares — an estimated $199 sold.

Barclays first reported a position in INFI in Q2 2013 and held it in 33 quarters. The position peaked at $3.98M in Q3 2014. 53 funds tracked by Wall St. Rank hold INFI as of Q1 2023.

  • Barclays reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Barclays sold 359 Infinity Pharmaceuticals, Inc. shares in Q1 2023, an estimated $199.
  • Barclays first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 33 quarters.
  • Barclays's Infinity Pharmaceuticals, Inc. position peaked at $3.98M in Q3 2014.
  • 53 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2023.

Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.